TP53 and breast carcinoma: In light of its increased frequency among the sub-population of Arab patients in Israel, TP53 p.Arg181Cys was included in 2020 as one of the pathogenic variants tested as part of the founder mutations panel recommended by the Israeli Ministry of Health to all Arab-Muslim breast cancer patients, regardless of their age at diagnosis.